From the Guidelines
Epoetin is contraindicated in patients with uncontrolled hypertension, known hypersensitivity to epoetin or its components, pure red cell aplasia (PRCA) that developed following treatment with any erythropoietin protein drugs, and certain malignancies where the goal is cure, particularly when treating anemia in cancer patients not receiving concurrent chemotherapy. According to the most recent evidence 1, epoetin should not be used in treatment of anemia associated with malignancy in patients who are not receiving concurrent myelosuppressive chemotherapy, with the exception of patients with lower risk myelodysplastic syndrome to avoid transfusions.
Key Contraindications
- Uncontrolled hypertension
- Known hypersensitivity to epoetin or its components
- Pure red cell aplasia (PRCA) that developed following treatment with any erythropoietin protein drugs
- Certain malignancies where the goal is cure, particularly when treating anemia in cancer patients not receiving concurrent chemotherapy
Important Considerations
- Epoetin carries a boxed warning regarding increased risk of death, serious cardiovascular events, stroke, and thromboembolism when administered to target hemoglobin levels greater than 11 g/dL
- Caution is warranted in patients with seizure disorders, thrombotic vascular disease, or those undergoing surgery, as epoetin may increase complications in these populations
- Regular monitoring of blood pressure, hemoglobin levels, and iron status is essential during treatment to minimize risks, as recommended by 1.
Additional Contraindications
- Hemoglobinopathies, such as sickle cell disease, may respond poorly to epoetin therapy, as noted in 1
- Folate and vitamin B12 deficiency can affect the response to epoetin, and investigation of cofactor adequacy is necessary in cases of loss of responsiveness to epoetin, as mentioned in 1
- Multiple myeloma, malnutrition, and hemolysis are also conditions that may affect the response to epoetin, as discussed in 1
From the FDA Drug Label
Uncontrolled hypertension Pure red cell aplasia (PRCA) that begins after treatment with Epogen or other erythropoietin protein drugs Serious allergic reactions to Epogen Use of the multiple-dose vials containing benzyl alcohol in neonates, infants, pregnant women, and lactating women
The contraindications for epocrit (epoetin) are:
- Uncontrolled hypertension
- Pure red cell aplasia (PRCA) that begins after treatment with epoetin or other erythropoietin protein drugs
- Serious allergic reactions to epoetin
- Use of the multiple-dose vials containing benzyl alcohol in:
From the Research
Contraindications for Epoetin (Erythropoietin)
The following are potential contraindications for epoetin (erythropoietin) therapy:
- Hypertension: Epoetin therapy has been associated with increased blood pressure and hypertension in some patients 3, 4, 5.
- Cardiovascular disease: Patients with pre-existing cardiovascular disease may be at increased risk of cardiovascular events, such as heart attacks and strokes, when treated with epoetin 6, 7.
- Chronic kidney disease: While epoetin is often used to treat anemia in patients with chronic kidney disease, it may also increase the risk of cardiovascular events and mortality in these patients 6, 4.
- High blood pressure: Patients with uncontrolled high blood pressure may be at increased risk of cardiovascular events when treated with epoetin 3, 5.
- Diabetes: Patients with diabetes may be at increased risk of cardiovascular events and mortality when treated with epoetin 6.
Special Considerations
- Patients receiving dialysis: These patients may be at increased risk of cardiovascular events and mortality when treated with epoetin 6.
- Patients with concurrent diabetes or high blood pressure: These patients may be at increased risk of cardiovascular events and mortality when treated with epoetin 6.
- Resistance to erythropoiesis-stimulating agents: Some patients may develop resistance to epoetin therapy, which can increase the risk of cardiovascular events and mortality 6.